Dean Investment Associates LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Dean Investment Associates LLC boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.0% in the 4th quarter, HoldingsChannel reports. The fund owned 29,253 shares of the medical equipment provider’s stock after buying an additional 4,866 shares during the quarter. Dean Investment Associates LLC’s holdings in Zimmer Biomet were worth $3,090,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Roman Butler Fullerton & Co. bought a new position in shares of Zimmer Biomet in the fourth quarter worth approximately $473,000. KLCM Advisors Inc. bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $7,825,000. Peddock Capital Advisors LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth about $654,000. Van ECK Associates Corp grew its stake in shares of Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after purchasing an additional 218,688 shares during the last quarter. Finally, Reinhart Partners LLC. increased its holdings in Zimmer Biomet by 34.4% during the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider’s stock valued at $9,164,000 after purchasing an additional 22,220 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Stock Down 0.2 %

Shares of ZBH opened at $97.10 on Thursday. Zimmer Biomet Holdings, Inc. has a 12-month low of $96.58 and a 12-month high of $123.96. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $19.33 billion, a PE ratio of 21.82, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The business’s 50 day moving average is $106.00 and its 200 day moving average is $106.85.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.99%. Zimmer Biomet’s payout ratio is 21.57%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ZBH. Raymond James cut their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. BTIG Research reiterated a “buy” rating on shares of Zimmer Biomet in a report on Monday. Royal Bank of Canada decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.